Cynata Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Cynata Therapeutics wird ein Gewinn- und Umsatzwachstum von 35.6% bzw. 51.8% pro Jahr prognostiziert, während der Gewinn pro Aktie um 53.6% pro Jahr wachsen soll.

Wichtige Informationen

35.6%

Wachstumsrate der Gewinne

53.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	15.9%
Wachstumsrate der Einnahmen	51.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	10 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?

May 29

We're A Little Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Rate

Feb 09

We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow

Feb 02

We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth

Sep 09

Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

May 26

Here's Why We're Not Too Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Dec 31

We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn

Aug 11

Gewinn- und Umsatzwachstumsprognosen

ASX:CYP - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (AUD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2026	7	-5	-4	-4	1
6/30/2025	1	-8	-8	-8	1
6/30/2024	2	-9	-9	-9	1
12/31/2023	2	-14	-12	-12	N/A
9/30/2023	2	-14	-13	-13	N/A
6/30/2023	2	-14	-14	-14	N/A
3/31/2023	2	-12	-12	-12	N/A
12/31/2022	3	-9	-10	-10	N/A
9/30/2022	5	-7	-7	-7	N/A
6/30/2022	8	-5	-3	-3	N/A
3/31/2022	8	-5	-2	-2	N/A
12/31/2021	8	-4	-1	-1	N/A
9/30/2021	5	-6	-3	-3	N/A
6/30/2021	2	-8	-5	-5	N/A
3/31/2021	2	-7	-5	-5	N/A
12/31/2020	3	-6	-5	-5	N/A
9/30/2020	5	-5	-4	-4	N/A
6/30/2020	7	-4	-3	-3	N/A
3/31/2020	6	-6	-5	-5	N/A
12/31/2019	4	-8	-7	-7	N/A
9/30/2019	3	-8	-7	-7	N/A
6/30/2019	1	-8	-7	-7	N/A
3/31/2019	1	-7	-6	-6	N/A
12/31/2018	1	-6	-5	-5	N/A
9/30/2018	1	-5	-4	-4	N/A
6/30/2018	1	-5	-4	-4	N/A
3/31/2018	1	-5	-4	-4	N/A
12/31/2017	1	-5	-5	-5	N/A
9/30/2017	2	-5	N/A	-4	N/A
6/30/2017	2	-5	N/A	-4	N/A
3/31/2017	2	-4	N/A	-3	N/A
12/31/2016	2	-3	N/A	-2	N/A
9/30/2016	1	-4	N/A	-3	N/A
6/30/2016	1	-5	N/A	-4	N/A
3/31/2016	1	-5	N/A	-4	N/A
12/31/2015	1	-5	N/A	-4	N/A
9/30/2015	1	-4	N/A	-4	N/A
6/30/2015	0	-4	N/A	-3	N/A
3/31/2015	0	-3	N/A	-2	N/A
12/31/2014	0	-3	N/A	-2	N/A
9/30/2014	0	-3	N/A	-2	N/A
6/30/2014	0	-3	N/A	-2	N/A
3/31/2014	0	-3	N/A	-1	N/A
12/31/2013	0	-2	N/A	-1	N/A
9/30/2013	0	-2	N/A	-1	N/A
6/30/2013	0	-1	N/A	-1	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CYP wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CYP wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CYP wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CYPDie Einnahmen des Unternehmens (51.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Australian (5.4% pro Jahr).

Hohe Wachstumseinnahmen: CYPDie Einnahmen des Unternehmens (51.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CYP in 3 Jahren voraussichtlich hoch sein wird

Cynata Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased to AU$2.00

Recent updates

Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?

Cynata Therapeutics Limited Completes Patient Enrolment in CYP-006TK Diabetic Foot Ulcer Clinical Trial

Cynata Therapeutics Limited Announces Updates on Phase 2 Clinical Trial of CYP-001

New minor risk - Financial position

We're A Little Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Rate

Cynata Therapeutics Limited Announces Resignation of David Atkins as Director

New major risk - Financial position

Cynata Therapeutics Limited Announces Management Appointments

We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow

Cynata Therapeutics Limited Receives IRB Approval for Proposed aGvHD Phase 2 Clinical Trial

Cynata Therapeutics Limited Receives Notice of Acceptance from IP Australia for Novel Application of Cymerus MSCs

LUMC to Fund New Clinical Trial of Cynata's Cymerus™ MSCs in Kidney Transplantation

Cynata Therapeutics Limited Receives Notice of Allowance for Australia & Canada Cymerus Patents

Cynata Therapeutics Limited Announces Successful Completion of Planned DSMB Review of DFU Trial

Cynata Therapeutics Limited, Annual General Meeting, Nov 22, 2022

Cynata Therapeutics Limited Receives Grant Award to Fund Study of Cynata Mscs in Heart Disease from Australian Government National Health and Medical Research Council

We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth

Cynata Therapeutics Limited Appoints Janine Rolfe as Independent Non-Executive Director, Effective 1 September 2022

Cynata Therapeutics Limited Announces Preclinical Study Showing Optimisation of CymerusTM MSCs for Coronary Artery Disease Published in Leading Peer-Reviewed Journal

Cynata Therapeutics Limited Receives Notice of Allowance from US Patent Office for Use of the Cymerus MSCs in Asthma

Cynata Therapeutics Limited Announces the Completion of A Pre-Clinical Study That Has Provided Further Evidence in Support of the Highly Potent Anti-Inflammatory Effects of Cynata's Proprietary Cymerus MSCs

Cynata Therapeutics Limited Adds New Site for MEMD Clinical Trial

United States Food and Drug Administration Clears IND for Cynata Therapeutics Limited's Phase 2 Clinical Trial of CYP-001 in GvHD

Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Price target decreased to AU$2.00

Cynata Therapeutics Limited Advances Clinical Trial in Diabetic Foot Ulcers

Cynata Therapeutics Limited Receives Decision to Grant A Patent in Japan

Cynata Therapeutics Limited Receives Decision to Grant A Patent in Japan

Here's Why We're Not Too Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Cynata Therapeutics Limited Commences DFU Clinical Trial

We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn

Cynata Therapeutics Limited Receives Approval by the Central Adelaide Local Health Network Human Research Ethics Committee to Commence A Clinical Trial

Cynata Therapeutics Limited Progresses Toward Clinical Trial in Diabetic Foot Ulcers

Cynata Therapeutics Limited Announces First Patient Enrolled in Cynata Mend Clinical Trial

Cynata Therapeutics Limited to Investigate New Study of the High Potency of Cymerus MSCs

New 90-day low: AU$0.64

New 90-day low: AU$0.66

New 90-day low: AU$0.74

Cynata Therapeutics Limited Announces Phase 3 Osteoarthritis Clinical Trial Commences

Cynata Therapeutics Limited Announces Positive Efficacy Data from A Study of Cymerustm Mesenchymal Stem Cells

New 90-day high: AU$1.03

New 90-day high - AU$0.79

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken